Group 1 - The company announced that its subsidiary, Tianfang Pharmaceutical Co., Ltd., has received the CEP certificate for Clindamycin Phosphate from the European Directorate for the Quality of Medicines (EDQM) [1][2] - The CEP certificate indicates that the product is qualified to enter the European market and other markets that recognize the CEP certificate, enhancing the company's international business prospects and global market competitiveness [2] Group 2 - As of the announcement date, there are 14 approved CEP certificates for Clindamycin Phosphate globally, with 9 being valid and 5 invalid [2] - The company plans to actively promote the production and sales of Clindamycin Phosphate, although future sales may be affected by industry policies and market conditions [2]

Group 1 - The core point of the article is that China Medical announced the approval of a CEP certificate for Clindamycin Phosphate by its subsidiary Tianfang Pharmaceutical from the European Directorate for the Quality of Medicines (EDQM) [1] Group 2 - The approval of the CEP certificate indicates that the product meets the European Pharmacopoeia standards, which may enhance the company's marketability in Europe [1] - This development could potentially open new avenues for revenue growth for the company in the European pharmaceutical market [1] - The issuance of the CEP certificate reflects the company's commitment to quality and compliance with international standards [1]

Core Viewpoint - China Pharmaceutical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. has received the Certificate of Suitability (CEP) for Clindamycin Phosphate from the European Directorate for the Quality of Medicines (EDQM), which enhances the company's ability to enter European and other markets that recognize the CEP certificate [1] Group 1 - The CEP certificate signifies that the Clindamycin Phosphate product meets the standards for chemical raw materials, allowing the company to expand its international business [1] - Clindamycin Phosphate is a lincosamide antibiotic primarily used for treating infections caused by Gram-positive bacteria and anaerobic bacteria [1] - The approval of the CEP certificate is expected to strengthen the company's product competitiveness in the global market [1]

Core Viewpoint - China Pharmaceutical announced that its wholly-owned subsidiary Tianfang Pharmaceutical received approval from the National Medical Products Administration for the listing application of fumaric acid volnorelaxin, which is primarily used for treating gastroesophageal reflux disease and eradicating Helicobacter pylori when used in conjunction with appropriate antibiotics [1] Group 1 - Tianfang Pharmaceutical has received the approval notice for fumaric acid volnorelaxin, indicating a significant advancement in its product pipeline [1] - The drug is intended for the treatment of gastroesophageal reflux disease and is used alongside antibiotics to eliminate Helicobacter pylori [1] - Additionally, Tianfang Pharmaceutical has obtained the European Pharmacopoeia suitability certificate for clindamycin phosphate, which is an antibiotic used for Gram-positive and anaerobic bacterial infections [1]

Core Viewpoint - China Pharmaceutical (600056) announced the approval of its subsidiary Tianfang Pharmaceutical's application for the active pharmaceutical ingredient Fumaric Acid Venlorasine by the National Medical Products Administration, indicating a significant advancement in its product pipeline [1] Group 1: Product Approvals - Tianfang Pharmaceutical received the approval notice for Fumaric Acid Venlorasine, which is primarily used for treating gastroesophageal reflux disease and in combination with appropriate antibiotics to eradicate Helicobacter pylori [1] - The company also obtained the European Pharmacopoeia suitability certificate for Clindamycin Phosphate, an antibiotic used for Gram-positive and anaerobic bacterial infections, from the European Medicines Agency [1]